Spoken Alpha
Larimar Therapeutics, Inc.
Larimar Therapeutics develops treatments for rare genetic diseases using a cell-penetrating peptide technology platform. The company's lead candidate, nomlabofusp, is a subcutaneously administered fusion protein designed to deliver the frataxin protein to mitochondria in patients with Friedreich's ataxia, a rare progressive neurodegenerative disease.
Larimar Therapeutics, Inc is a Healthcare company operating in Biotechnology with a $402.5M market cap.
Most recent reported earnings: Q3 FY2026 (Nov 3, 2026).
Behavioral analysis
Disclosures
Extracted from Unknown source, 2026-08-30.
Transcripts
Most recent calls indexed for this ticker. Open any call to drill into prepared remarks and Q&A.
History
Executives who appear on this company's earnings calls in our corpus, with role and tenure sourced from SEC filings. Click any name for the full role timeline and call appearance history. Per-executive behavioral deviation metrics are available to research subscribers.
Peers
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for LRMR.
$ curl https://api.spokenalpha.com/v1/companies/LRMRFAQ
Spoken Alpha indexes LRMR's earnings call transcripts at https://spokenalpha.com/companies/LRMR. Each call links to attributed speakers and parsed analyst Q&A. Larimar Therapeutics, Inc.'s own investor relations page is at https://investors.larimartx.com/.
Larimar Therapeutics, Inc. (LRMR) held its most recent earnings call on 2025-09-29, covering fiscal Q1 2023.
Larimar Therapeutics, Inc. (LRMR) operates in the Healthcare sector (Biotechnology industry).
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q3 FY2026 | 2026-11-03 | — | $-0.39 | — | — | — | — | EODHD |
| Q2 FY2026 | 2026-08-03 | $-0.30 | $-0.39 | +23.1% | $0 | — | — | EODHD |
| Q1 FY2026 | 2026-05-13 | $-0.31 | $-0.59 | +47.5% | $0 | — | — | EODHD |
| Q4 FY2025 | 2026-03-17 | $-0.73 | $-0.49 | -49.0% | $0 | — | — | EODHD |
| Q3 FY2025 | 2025-11-04 | $-0.61 | $-0.39 | -56.4% | $0 | — | — | EODHD |
| Q2 FY2025 | 2025-08-13 | $-0.41 | $-0.49 | +16.3% | $0 | — | — | EODHD |
| Q1 FY2025 | 2025-04-29 | $-0.46 | $-0.41 | -12.2% | $0 | — | — | EODHD |
| Q4 FY2024 | 2025-03-11 | $-0.45 | $-0.32 | -40.9% | $482.0K | — | — | EODHD |
| Q3 FY2024 | 2024-10-29 | $-0.24 | $-0.37 | +35.1% | $0 | — | — | EODHD |
| Q2 FY2024 | 2024-08-06 | $-0.34 | $-0.32 | -6.3% | $0 | — | — | EODHD |
| Q1 FY2024 | 2024-05-08 | $-0.27 | $-0.24 | -12.5% | $0 | — | — | EODHD |
| Q4 FY2023 | 2024-03-13 | $-0.30 | $-0.25 | -20.0% | $0 | — | — | EODHD |
| Q3 FY2023 | 2023-11-13 | $-0.21 | $-0.23 | +8.7% | $0 | — | — | EODHD |
| Q2 FY2023 | 2023-08-09 | $-0.19 | $-0.21 | +9.5% | $0 | — | — | EODHD |
| Q1 FY2023 | 2023-05-14 | $-0.15 | $-0.25 | +40.0% | $0 | — | — | EODHD |
| Q4 FY2022 | 2023-03-13 | $-0.21 | $-0.37 | +43.2% | $0 | — | — | EODHD |
| Q3 FY2022 | 2022-11-09 | $-0.37 | $-0.42 | +11.9% | $0 | — | — | EODHD |
| Q2 FY2022 | 2022-08-10 | $-0.47 | $-0.57 | +17.5% | $0 | — | — | EODHD |
| Q1 FY2022 | 2022-05-11 | $-0.49 | $-0.51 | +3.9% | $0 | — | — | EODHD |
| Q4 FY2021 | 2022-03-24 | $-0.50 | $-0.72 | +30.6% | $0 | — | — | EODHD |
Source: EODHD. LRMR reported actuals as published; sparse fields render as —.